Literature DB >> 60057

Quantitation of antibodies to Herpes simplex virus types 1 and 2 by complement-dependent antibody lysis of infected cells.

H McClung, P Seth, W E Rawls.   

Abstract

The release of 51Cr from cells infected with herpes simplex virus type 1 or type 2 by antibody and complement was examined as a method of quantitating antibodies to the viruses. With decreasing concentration of antibody, a typical dose-response curve was observed; a region of antibody excess in which dilution did not affect percentage of specific 51Cr release followed by a region in which a linear relation existed between dilution and percentage of specific 51Cr release. Therefore, a quantitative expression of antibody titer was defined as that dilution of serum which yielded 50% specific 51Cr release. The slopes of the linear portion of the dose-response curves were characteristic of the type of virus used to infect the cells and not upon the source of antiserum, thus, the slopes could be used to estimate antibody titers. The multiplicity of infection influenced the antibody titers; reproducible results were obtained when cultures were infected with 3 to 5 plaque-forming units per cell; the antibody titers decreased when less virus was used. The antibody titers obtained by the 51Cr release test were similar to those obtained by a microneutralization test. The 51Cr release test was found to be reproducible and to be useful in estimating the percentages of antibody activity attributable to antibodies to cross-reacting and type-specific antigens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60057     DOI: 10.1093/oxfordjournals.aje.a112288

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  11 in total

1.  Experimental ulcerative herpetic keratitis. III. Evaluation of hyperimmune gammaglobulin therapy.

Authors:  C A Carter; D L Easty
Journal:  Br J Ophthalmol       Date:  1981-06       Impact factor: 4.638

2.  Studies on the neutralizing antibody to herpes simplex virus. II. Quantitative analysis of type specific antibodies in rabbits immunized with both types of virus.

Authors:  M Ohashi; Y Ozaki
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

3.  Rapid typing of herpes simplex virus isolates by deoxyribonucleic acid:deoxyribonucleic acid hybridization.

Authors:  A R Brautigam; D D Richman; M N Oxman
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

4.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

5.  Isolation of the major herpes simplex virus type 1 (HSV-1)-specific glycoprotein by hydroxylapatite chromatography and its use in enzyme-linked immunosorbent assay for titration of human HSV-1-specific antibodies.

Authors:  B F Vestergaard; P C Grauballe
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

6.  Glycoproteins of herpes simplex virus type 2 as defined by monoclonal antibodies.

Authors:  N Balachandran; D Harnish; W E Rawls; S Bacchetti
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

7.  Comparison of indirect hemagglutination and 51chromium release tests for detection of Herpes Simplex Virus type 1 and 2 antibodies in patients with recurrent Herpes infections.

Authors:  L Kesavalu; P Seth
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Comparison of antibody-dependent cellular cytotoxicity and complement-dependent antibody lysis of herpes simplex virus-infected cells as methods of detecting antiviral antibodies in human sera.

Authors:  T Subramanian; W E Rawls
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

9.  Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay.

Authors:  S Jeansson; M Forsgren; B Svennerholm
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

10.  Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro.

Authors:  Andrew P Cap; Heather F Pidcoke; Shawn D Keil; Hilary M Staples; Manu Anantpadma; Ricardo Carrion; Robert A Davey; Ashley Frazer-Abel; Audra L Taylor; Richard Gonzales; Jean L Patterson; Raymond P Goodrich
Journal:  Transfusion       Date:  2016-03       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.